Monthly
US$200
Billed every month
Trazodone Hydrochloride Tablets(盐酸曲唑酮片)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 3 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders21View records ↓
Under-review filings5View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers36View records ↓
API companies with A status8View records ↓
Chemical-drug catalogue
Loaded records: 21 holders; 1 in the quality-and-efficacy consistency-evaluation category, and 18 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 合肥英太制药有限公司 | 合肥英太制药有限公司 | 国药准字H20266093 | 2026/09/22 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 合肥英太制药有限公司 | 合肥英太制药有限公司 | 国药准字H20266094 | 2026/09/22 | 25mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏万高药业股份有限公司 | 江苏万高药业股份有限公司 | 国药准字H20265850 | 2026/09/02 | 25mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏万高药业股份有限公司 | 江苏万高药业股份有限公司 | 国药准字H20265849 | 2026/09/02 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 安徽万邦医药科技股份有限公司 | 吉林天衡英睿制药有限公司 | 国药准字H20264942 | 2026/06/23 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福建东瑞制药有限公司 | 深圳信立泰药业股份有限公司 | 国药准字H20264571 | 2026/05/27 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福建东瑞制药有限公司 | 深圳信立泰药业股份有限公司 | 国药准字H20264572 | 2026/05/27 | 100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 仁合益康集团有限公司 | 河北仁合益康药业有限公司 | 国药准字H20264228 | 2026/05/07 | 25mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 仁合益康集团有限公司 | 河北仁合益康药业有限公司 | 国药准字H20264227 | 2026/05/07 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川科伦药业股份有限公司 | 四川科伦药业股份有限公司 | 国药准字H20263247 | 2026/01/27 | 25mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川科伦药业股份有限公司 | 四川科伦药业股份有限公司 | 国药准字H20263246 | 2026/01/27 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江江北药业有限公司 | 浙江江北药业有限公司 | 国药准字H20263152 | 2026/01/20 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京福元医药股份有限公司 | 北京福元医药股份有限公司 | 国药准字H20263075 | 2026/01/14 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福建省闽东力捷迅药业股份有限公司 | 福建省闽东力捷迅药业股份有限公司 | 国药准字H20256267 | 2025/12/16 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福建省闽东力捷迅药业股份有限公司 | 福建省闽东力捷迅药业股份有限公司 | 国药准字H20256266 | 2025/12/16 | 25mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江诺得药业有限公司 | 浙江诺得药业有限公司 | 国药准字H20256265 | 2025/12/16 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福安药业集团宁波天衡制药有限公司 | 福安药业集团宁波天衡制药有限公司 | 国药准字H20256259 | 2025/12/16 | 100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福安药业集团宁波天衡制药有限公司 | 福安药业集团宁波天衡制药有限公司 | 国药准字H20256258 | 2025/12/16 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华益泰康药业股份有限公司 | 华益泰康药业股份有限公司 | 国药准字H20256138 | 2025/12/03 | 25mg | Not stated by source | CDE |
| 华益泰康药业股份有限公司 | 华益泰康药业股份有限公司 | 国药准字H20256137 | 2025/12/03 | 50mg | Not stated by source | CDE |
| 成都倍特药业股份有限公司 | 成都倍特药业股份有限公司 | 国药准字H20256042 | 2025/11/25 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆圣华曦药业股份有限公司 | 重庆圣华曦药业股份有限公司 | 国药准字H20255746 | 2025/10/21 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 沈阳福宁药业有限公司 | 沈阳福宁药业有限公司 | 国药准字H20050223 | 2025/08/18 | 50mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 河北龙海药业有限公司 | 河北龙海药业有限公司 | 国药准字H20254859 | 2025/07/15 | 50mg | Not stated by source | CDE |
| 西安远大科创医药科技有限公司 | 西安远大德天药业股份有限公司 | 国药准字H20254735 | 2025/06/30 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江西科睿药业有限公司 | 江西科睿药业有限公司 | 国药准字H20254738 | 2025/06/30 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 深圳市泛谷药业股份有限公司 | 吉林天衡英睿制药有限公司 | 国药准字H20254458 | 2025/06/03 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆海默尼制药有限公司 | 华益药业科技（安徽）有限公司 | 国药准字H20263526 | 2026/03/10 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 远大医药（西安）有限公司 | 西安远大德天药业股份有限公司 | 国药准字H20269186 | 2026/07/31 | 25mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 36 distinct approval numbers and 22 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京福元医药股份有限公司 | 国药准字H20263075 | 50mg | Category B (乙) | XN06AXQ113A001010100177 | NHSA |
| 沈阳华泰药物研究有限公司 | 国药准字H20133205 | 100mg | Category B (乙) | XN06AXQ113A001010101287 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20256042 | 50mg | Category B (乙) | XN06AXQ113A001010102013 | NHSA |
| 四川科伦药业股份有限公司 | 国药准字H20263247 | 25mg | Category B (乙) | XN06AXQ113A001010102180 | NHSA |
| 山东信谊制药有限公司 | 国药准字H20254859 | 50mg | Category B (乙) | XN06AXQ113A001010102766 | NHSA |
| 福安药业集团宁波天衡制药有限公司 | 国药准字H20256258 | 50mg | Category B (乙) | XN06AXQ113A001010104561 | NHSA |
| 福建省闽东力捷迅药业股份有限公司 | 国药准字H20256266 | 25mg | Category B (乙) | XN06AXQ113A001010104799 | NHSA |
| 福建东瑞制药有限公司 | 国药准字H20264571 | 50mg | Category B (乙) | XN06AXQ113A001010104876 | NHSA |
| 华益泰康药业股份有限公司 | 国药准字H20256138 | 25mg | Category B (乙) | XN06AXQ113A001010105819 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20255746 | 50mg | Category B (乙) | XN06AXQ113A001010109568 | NHSA |
| 台湾海默尼药业有限公司 | 国药准字J20190011 | 50mg/片 | Category B (乙) | XN06AXQ113A001010110427 | NHSA |
| 台湾海默尼药业有限公司 | HC20171014 | 50mg/片 | Category B (乙) | XN06AXQ113A001010179116 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20263152 | 50mg | Category B (乙) | XN06AXQ113A001010179303 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20266093 | 50mg | Category B (乙) | XN06AXQ113A001010180698 | NHSA |
| 台湾海默尼药业有限公司 | 国药准字HC20191000 | 50mg/片 | Category B (乙) | XN06AXQ113A001010182195 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20264228 | 25mg | Category B (乙) | XN06AXQ113A001010183033 | NHSA |
| 深圳市泛谷药业股份有限公司 | 国药准字H20254458 | 50mg | Category B (乙) | XN06AXQ113A001010183251 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001010183521 | NHSA |
| 远大医药(西安)有限公司 | 国药准字H20254735 | 50mg | Category B (乙) | XN06AXQ113A001010184146 | NHSA |
| 江西科睿药业有限公司 | 国药准字H20254738 | 50mg | Category B (乙) | XN06AXQ113A001010184736 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20263075 | 50mg | Category B (乙) | XN06AXQ113A001010200177 | NHSA |
| 沈阳华泰药物研究有限公司 | 国药准字H20133205 | 100mg | Category B (乙) | XN06AXQ113A001010201287 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20256042 | 50mg | Category B (乙) | XN06AXQ113A001010202013 | NHSA |
| 四川科伦药业股份有限公司 | 国药准字H20263247 | 25mg | Category B (乙) | XN06AXQ113A001010202180 | NHSA |
| 福建东瑞制药有限公司 | 国药准字H20264571 | 50mg | Category B (乙) | XN06AXQ113A001010204876 | NHSA |
| 华益泰康药业股份有限公司 | 国药准字H20256138 | 25mg | Category B (乙) | XN06AXQ113A001010205819 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20255746 | 50mg | Category B (乙) | XN06AXQ113A001010209568 | NHSA |
| 台湾海默尼药业有限公司 | 国药准字J20190011 | 50mg/片 | Category B (乙) | XN06AXQ113A001010210427 | NHSA |
| 台湾海默尼药业有限公司 | 国药准字HC20171014 | 50mg/片 | Category B (乙) | XN06AXQ113A001010279116 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20266093 | 50mg | Category B (乙) | XN06AXQ113A001010280698 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001010283521 | NHSA |
| 江西科睿药业有限公司 | 国药准字H20254738 | 50mg | Category B (乙) | XN06AXQ113A001010284736 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20263075 | 50mg | Category B (乙) | XN06AXQ113A001010300177 | NHSA |
| 福建东瑞制药有限公司 | 国药准字H20264571 | 50mg | Category B (乙) | XN06AXQ113A001010304876 | NHSA |
| 华益泰康药业股份有限公司 | 国药准字H20256138 | 25mg | Category B (乙) | XN06AXQ113A001010305819 | NHSA |
| 重庆海默尼制药有限公司 | 国药准字H20263526 | 50mg | Category B (乙) | XN06AXQ113A001010310427 | NHSA |
| 台湾海默尼药业有限公司 | 国药准字HC20171014 | 50mg/片 | Category B (乙) | XN06AXQ113A001010379116 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20266093 | 50mg | Category B (乙) | XN06AXQ113A001010380698 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001010383521 | NHSA |
| 常州华生制药有限公司 | 国药准字H20020355 | 50mg | Category B (乙) | XN06AXQ113A001010401371 | NHSA |
| 重庆海默尼制药有限公司 | 国药准字H20263526 | 50mg | Category B (乙) | XN06AXQ113A001010410427 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001010483521 | NHSA |
| 常州华生制药有限公司 | 国药准字H20020355 | 50mg | Category B (乙) | XN06AXQ113A001010501371 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001010583521 | NHSA |
| 常州华生制药有限公司 | 国药准字H20020355 | 50mg | Category B (乙) | XN06AXQ113A001010601371 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001010683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001010783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001010883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001010983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001011083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001011183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001011283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001011383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001011483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001011583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001011683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001011783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001011883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001011983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001012083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001012183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001012283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001012383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001012483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001012583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001012683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001012783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001012883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001012983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001013083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001013183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001013283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001013383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001013483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20256265 | 50mg | Category B (乙) | XN06AXQ113A001013583521 | NHSA |
| 沈阳华泰药物研究有限公司 | 国药准字H20060037 | 25mg | Category B (乙) | XN06AXQ113A001020101287 | NHSA |
| 四川科伦药业股份有限公司 | 国药准字H20263246 | 50mg | Category B (乙) | XN06AXQ113A001020102180 | NHSA |
| 福安药业集团宁波天衡制药有限公司 | 国药准字H20256259 | 100mg | Category B (乙) | XN06AXQ113A001020104561 | NHSA |
| 福建省闽东力捷迅药业股份有限公司 | 国药准字H20256267 | 50mg | Category B (乙) | XN06AXQ113A001020104799 | NHSA |
| 福建东瑞制药有限公司 | 国药准字H20264572 | 100mg | Category B (乙) | XN06AXQ113A001020104876 | NHSA |
| 华益泰康药业股份有限公司 | 国药准字H20256137 | 50mg | Category B (乙) | XN06AXQ113A001020105819 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20266094 | 25mg | Category B (乙) | XN06AXQ113A001020180698 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20264227 | 50mg | Category B (乙) | XN06AXQ113A001020183033 | NHSA |
| 深圳市泛谷药业股份有限公司 | 国药准字H20254459 | 100mg | Category B (乙) | XN06AXQ113A001020183251 | NHSA |
| 沈阳华泰药物研究有限公司 | 国药准字H20060037 | 25mg | Category B (乙) | XN06AXQ113A001020201287 | NHSA |
| 福建东瑞制药有限公司 | 国药准字H20264572 | 100mg | Category B (乙) | XN06AXQ113A001020204876 | NHSA |
| 华益泰康药业股份有限公司 | 国药准字H20256137 | 50mg | Category B (乙) | XN06AXQ113A001020205819 | NHSA |
| 台湾海默尼药业有限公司 | 国药准字HC20171014 | 50mg/片 | Category B (乙) | XN06AXQ113A001020279116 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20266094 | 25mg | Category B (乙) | XN06AXQ113A001020280698 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20264227 | 50mg | Category B (乙) | XN06AXQ113A001020283033 | NHSA |
| 福建东瑞制药有限公司 | 国药准字H20264572 | 100mg | Category B (乙) | XN06AXQ113A001020304876 | NHSA |
| 华益泰康药业股份有限公司 | 国药准字H20256137 | 50mg | Category B (乙) | XN06AXQ113A001020305819 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20266094 | 25mg | Category B (乙) | XN06AXQ113A001020380698 | NHSA |
| 沈阳华泰药物研究有限公司 | 国药准字H20050223 | 50mg | Category B (乙) | XN06AXQ113A001030101287 | NHSA |
| 沈阳华泰药物研究有限公司 | 国药准字H20050223 | 50mg | Category B (乙) | XN06AXQ113A001030201287 | NHSA |
| 沈阳华泰药物研究有限公司 | 国药准字H20050223 | 50mg | Category B (乙) | XN06AXQ113A001030301287 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20265849 | 50mg | Category B (乙) | XN06AXQ113A001010101503 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20266284 | 50mg | Category B (乙) | XN06AXQ113A001010104339 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20265849 | 50mg | Category B (乙) | XN06AXQ113A001010201503 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20266284 | 50mg | Category B (乙) | XN06AXQ113A001010204339 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20265849 | 50mg | Category B (乙) | XN06AXQ113A001010301503 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20266284 | 50mg | Category B (乙) | XN06AXQ113A001010304339 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20265849 | 50mg | Category B (乙) | XN06AXQ113A001010401503 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20266284 | 50mg | Category B (乙) | XN06AXQ113A001010404339 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20265849 | 50mg | Category B (乙) | XN06AXQ113A001010501503 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20266284 | 50mg | Category B (乙) | XN06AXQ113A001010504339 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20265849 | 50mg | Category B (乙) | XN06AXQ113A001010601503 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20265849 | 50mg | Category B (乙) | XN06AXQ113A001010701503 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20265849 | 50mg | Category B (乙) | XN06AXQ113A001010801503 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20265850 | 25mg | Category B (乙) | XN06AXQ113A001020101503 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20265850 | 25mg | Category B (乙) | XN06AXQ113A001020201503 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20265850 | 25mg | Category B (乙) | XN06AXQ113A001020301503 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20265850 | 25mg | Category B (乙) | XN06AXQ113A001020401503 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 5 filings and 4 distinct first applicants.
Generic 2 · Supplement 3
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 重庆世森医药科技有限公司;烟台鲁银药业有限公司 | CYHS2600647 | Generic | 2026/03/12 | Not stated by source | CDE |
| Lotus Pharmaceutical Co. Ltd. Nantou Plant;Chongqing Hemony Pharmaceutical Co. Ltd | JYHB2650002 | Supplement | 2026/09/01 | Not stated by source | CDE |
| Lotus Pharmaceutical Co. Ltd. Nantou Plant | JYHB2650001 | Supplement | 2026/09/01 | Not stated by source | CDE |
| 沈阳华泰药物研究有限公司;沈阳福宁药业有限公司 | CYHB2601501 | Supplement | 2026/08/05 | Not stated by source | CDE |
| 三金集团湖南三金制药有限责任公司 | CYHS2600911 | Generic | 2026/04/21 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
API registrations
Non-component matches: 8 companies with A status and 8 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 盐酸曲唑酮 | 合肥立方制药股份有限公司 | Y20260000741 | I | Exact ingredient | 2026/08/21 | CDE |
| 盐酸曲唑酮 | 河北广祥制药有限公司 | Y20260000137 | I | Exact ingredient | 2026/03/03 | CDE |
| 盐酸曲唑酮 | 山东安信制药有限公司 | Y20250000875 | I | Exact ingredient | 2025/11/04 | CDE |
| 盐酸曲唑酮 | 兰西哈三联制药有限公司 | Y20250000868 | I | Exact ingredient | 2025/08/26 | CDE |
| 盐酸曲唑酮 | 植恩生物技术股份有限公司 | Y20250000281 | I | Exact ingredient | 2025/03/26 | CDE |
| 盐酸曲唑酮 | Granules India Limited.Unit-Ⅳ | Y20240001042 | I | Exact ingredient | 2024/11/18 | CDE |
| 盐酸曲唑酮 | Arene Life Sciences Private Limited | Y20240000118 | I | Exact ingredient | 2024/07/31 | CDE |
| 盐酸曲唑酮 | 四川仁安药业有限责任公司 | Y20240000132 | A | Exact ingredient | 2026/09/12 | CDE |
| 盐酸曲唑酮 | 湖南九典宏阳制药有限公司 | Y20230001003 | A | Exact ingredient | 2026/06/02 | CDE |
| 盐酸曲唑酮 | Medilux Laboratories Pvt. Ltd. | Y20220000900 | A | Exact ingredient | 2026/09/16 | CDE |
| 盐酸曲唑酮 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO ACRAF SPA | Y20220000333 | A | Exact ingredient | 2025/09/15 | CDE |
| 盐酸曲唑酮 | Matrix Pharmacorp Private Limited | Y20210000921 | A | Exact ingredient | 2026/09/16 | CDE |
| 盐酸曲唑酮 | Piramal Pharma Limited | Y20210000635 | A | Exact ingredient | 2023/08/14 | CDE |
| 盐酸曲唑酮 | 常州华生制药有限公司 | Y20190004670 | A | Exact ingredient | 2025/07/24 | CDE |
| 盐酸曲唑酮 | 沈阳福宁药业有限公司 | Y20190002723 | A | Exact ingredient | 2024/07/03 | CDE |
| 盐酸曲唑酮 | 浙江华海药业股份有限公司 | Y20260000948 | I | Exact ingredient | 2026/11/09 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/09/02Accepted
济宁神州医药有限公司;吉林天衡英睿制药有限公司
CYHB2601674
Fact date: 2026/09/02 · Site observation date: 2026/10/22
View source ↗ -
2026/09/01Accepted
Lotus Pharmaceutical Co. Ltd. Nantou Plant;Chongqing Hemony Pharmaceutical Co. Ltd
JYHB2650002
Fact date: 2026/09/01 · Site observation date: 2026/10/22
View source ↗ -
2026/09/01Accepted
Lotus Pharmaceutical Co. Ltd. Nantou Plant
JYHB2650001
Fact date: 2026/09/01 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Trazodone Hydrochloride Tablets
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy